• ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • LEGAL & INVESTMENT TEAM
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • AIM RULE 26
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US
Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"
NSCI (LON) 5,25 GBX
  • ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • LEGAL & INVESTMENT TEAM
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • AIM RULE 26
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US

ProAxsis to initiate clinical trial partnership with National Jewish Health for its ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease Patients

Oct 27, 2017
-
News, RNS Announcements, Wanda Health

London, UK – October 27th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, provides an update on its portfolio company ProAxsis, which today announces that it has entered into a clinical trial partnership with National Jewish Health (“NJH”), the leading respiratory hospital in the United States.

Under the agreement ProAxis and NJH will work together in validating ProAxsis’ ProteaseTag® point-of-care technology for real-time management of small airway inflammation in a spectrum of respiratory diseases including cystic fibrosis and COPD.

Commenting on the news, Francois Martelet, Chief Executive Officer of NetScientific and Chairman of ProAxsis, said: “We are delighted to note this US partnership with National Jewish Health, one of the world’s leading hospitals in respiratory disease. The partnership brings tremendous resources and expertise and validates ProAxsis’ technology as a potential industry leader for respiratory diagnostics.  Our portfolio company, ProAxsis is very excited to work closely with NJH as they continue to make commercial progress.”

 

NetScientific holds a 57% stake on a fully diluted basis in ProAxsis.

 

The full text of the announcement from ProAxsis can be found below.

 

 

#  #  #

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson /

Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
 

ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health

Date: October 27th, 2017

ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate ProAxsis Limited’s ProteaseTag® point-of-care technology for real-time management of small airway inflammation in a spectrum of respiratory diseases including Cystic Fibrosis and COPD. ProAxsis’ technology will allow clinicians to measure active Neutrophil Elastase as a potential predictor of chronic respiratory disease exacerbations and severity in COPD and cystic fibrosis, and offers a potential companion diagnostic for disease modifying agents. COPD affects more than 24 million Americans, and is the third leading cause of death.  National Jewish Health is the #1 ranked Hospital in Respiratory Disease by US News and World Report 2017.

 

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “National Jewish Health is a globally recognised leader in respiratory care and research, so this agreement brings tremendous resources and expertise to our effort to bring the ProteaseTag® technology to market in the US.”

 

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

About ProAxsis Limited

 

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. Its first immunoassay measures active neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. A rapid point-of-care test for measuring neutrophil elastase, called NEATstik®, was registered with a CE Mark in September 2017.  The laboratory-based immunoassays and point-of-care tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies.  The company is also supported by QUBIS, the commercialisation arm of Queens University.

 

FacebookTweetGoogle+Linkedin
← PREVIOUS POST
ProAxsis to Showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
NEXT POST →
Directorate Change
News
  • Conclusion of Strategic Review
  • Glycotest Inc. Receives $3 Million Initial Tranche from $10 Million Series A Financing
  • Termination of Formal Sale Process
  • Update on Strategic Review
  • Form 8 (OPD) – NetScientific (Offeree)
INVESTORS
  • Investors
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • AIM Rule 26
  • News
Categories
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
  • Vortex BioSciences
  • Wanda Health
Archives
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

NetScientific plc

6 Bevis Marks
1st floor, Bury Court
London
EC3A 7BA

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • Investors
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • AIM Rule 26
  • News
copyright
Terms of Use
ProAxsis to initiate clinical trial partnership with National Jewish Health for its ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease Patients - NetScientific